IN PARTNERSHIP
What’s the story of Dryce? We were born in 1998 from a joint venture between Gruppo Marotta and Rivoira, a company that is now part of the multinational group Nippon Gases, a leader in the production and distribution of gases and development of new technologies. In the beginning, Dryce dedicated itself to production and distribution of dry ice (solid carbon dioxide). Over the years the company has gradually diversified, expanding and completing its range of products. So it has managed to stand out in the market in terms of both innovation and know-how, providing its customers with the best solutions available and thus becoming one of the major players in the Italian and European market.
Temperature-controlled transportation and storage of drugs is a need that has had a further ‘crash test’ in the case of vaccines: could you explain how you have proceeded? We immediately took action by offering our advice and fine-tuning our solutions and thermoblocks according to the specific organisational needs involved in the distribution of vaccines. We are able to design and implement solutions to cope with the different scenarios that characterise the cold chain, taking into account all the variables: type of product to be transported; size and quantity; minimum and maximum temperature required; duration of transport (short, medium, long range); and external temperature conditions to which the goods will be exposed during transportation. In accordance with current regulation, the system is designed by selecting the materials to be used in the construction of packaging, the type of refrigerant mass defined according to the temperature range to be managed (dry ice or phase change materials, PCMs). We realise the optimal configuration by exploiting advanced simulation software and climatic chamber that certify and validate the proposed systems. The goal is to ensure full compliance with the cold chain, to protect pharmaceutical products and therefore patients and their health.
Do you consider you won the challenge of vaccine transportation during the pandemic? In the Italian experience on managing vaccine doses, Dryce has offered its know-how and its products to give concrete help to the Italian national health service in order to safely transport doses of COVID-19 vaccines across the national
territory. We weren’t taken by surprise by the emergency and the urgency to act. Dryce has temperature-controlled transport in its DNA. This benefited the system and facilitated the entire vaccination process on Italian territory. We can define it as a success and a best practice of absolute value for the health of citizens.
Italian territory is variegated, and the regional health system has thrown up some critical issues. How did you manage them? We set up the work by involving the main hubs and the peripheries. Dryce managed to implement a process shared with the institutions and proved itself a reliable partner. We have benefited from operational continuity, despite the change of the central government and the emergency commissary, thus managing to guarantee the supply of certified systems in a very short time to meet the various needs of vaccine transport.
You passed the production test: how did you do it?
Thanks to the wide availability of raw materials, to production plants of great capacity and efficiency, to a solid network of partner suppliers and, above all, thanks to the availability of the people who work in Dryce, we have always managed to support the large supplies requested while respecting the pre-established deadlines.
What are the latest ongoing collaborations and your next challenges? During recent months, we have defined, together with the Italian Society of Hospital Pharmacists (ISHP), an experiment for monitoring the transportation of vaccines in some health authorities during what is called the ‘last mile’. The collected data showed that the system
developed by Dryce allows it to operate safely, guaranteeing the transportation of vaccines even with summer external temperatures. A strong all-round commitment is needed because the management of the pandemic and the vaccination campaign could not and cannot foresee grey areas. Pride appears in the eyes and in the words of Carmine Marotta (CEO of Dryce), who immediately took action so that the Italian health system could offer citizens and patients the vaccine, from the main hubs to the most extreme suburbs. It takes commitment, competence and heart to export.
Clinical Trial Supply Handbook | 9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
